After 10 days of antibiotic therapy, hyperhidrosis regressed together with the clinical manifestations. According to these data, we hypothesize that hyperhidrosis is find more due to an eccrine sweat gland hyperfunction, probably secondary to bacterial infection.”
“The objective of this study was to produce green phenolic resins and adhesives using bio-phenolic compounds produced from lignin/forestry residuals. To produce bio-phenolic compounds, an organosolv lignin (OL) was catalytically degraded in 50/50 (v/v) water-ethanol

and pure ethanol media under sub/supercritical condition in hydrogen atmosphere. Effects of lignin degradation process conditions (catalyst, temperature, type of reactor, etc.) on the yields and properties

(molecular weights) of the degraded lignin selleck chemical (DL) products were examined in this study. The DL products were used to substitute for phenol in the synthesis of bio-phenol formaldehyde resins, denoted as degraded lignin phenol-formaldehyde (DLPF) resins, whose properties (such as viscosity, non-volatile contents, storage time, free formaldehyde contents, curing behavior, and thermal stability) were compared with pure PF resin and organosolv lignin phenol-formaldehyde (OLPF) resins. Plywood samples glued with the OLPF and DLPF adhesives with a phenol replacement ratio up to 75 wt% showed higher dry and wet tensile strengths than those of PF adhesives. Although the OLPF adhesives have better bond strengths and thermal stability than DLPF adhesives, the DLPF resins have a lower free formaldehyde content and can be cured at a lower temperature. (C) 2012 Elsevier B.V. All rights reserved.”
“The practice of prostate-specific antigen (PSA) screening has been increasing in Italy despite uncertain scientific evidence and contrary recommendations from most scientific societies. In 2002, a survey of PSA screening diffusion among general practices was performed, looking for screening frequency and age pattern of screened individuals. The objective of this study was to assess whether the features of PSA screening

did change after 6 years in the same considered setting. Using 8-Bromo-cAMP mouse the data obtained from 500 Italian general practitioners providing information to the Health Search/CSD Patient database, we selected, for the study purpose 351 091 male individuals. We assumed PSA prescriptions performed during 2005-2008 in individuals without prostate cancer, or benign prostate disease, or urological symptoms history to have a screening purpose. Screening frequency was analyzed in the overall series, by year and by patient’s age. Exposure to PSA screening (at least on PSA test in the considered period) of males aged over 50 years raised from 31.4% (confidence interval 95% 31.08-31.70%) during 2002 to 46.4% (confidence interval 95% 46.19-46.68%) during 2008.